- Workpackage leader
Prof Felix Rosenow - Participants
- Objectives of the Workpackage
Brain stimulation (for example, vagus nerve stimulation) has emerged as an alternative therapeutic approach to treat patients with drug-resitant epilepsy. The global epilepsy neurostimulation market is expected to reach $480 million in 2014 and potentially 1.9 million patients with epilepsy could benefit. Methods to identify which patients could benefit would radically impact the market. Led by Professors Hamer and Rosenow, this workpackage will identify the microRNA changes that accompany stimulation parameters which alter seizures and protect the brain. In parallel, a clinical trial will profile miRNA changes triggered by brain stimulation devices in epilepsy patients.
